Abbott Laboratories (Pakistan) (KAR:ABOT) Research & Development: ₨142 Mil (TTM As of Mar. 2026)


KAR:ABOT Abbott Laboratories (Pakistan) Ltd KAR:ABOT
77 GF Score
Price ₨966.44
GF Value ₨1,001.38
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Abbott Laboratories (Pakistan) Research & Development?

Abbott Laboratories (Pakistan) KAR:ABOT 77 Research & Development is ₨142 Mil as of Mar. 2026. GuruFocus rates KAR:ABOT with a GF Score™ of 77/100 and a GF Value™ of ₨1,001.38 (Fairly Valued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Abbott Laboratories (Pakistan)'s Research & Development for the three months ended in Mar. 2026 was ₨33 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₨142 Mil.

Abbott Laboratories (Pakistan)  (KAR:ABOT) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Abbott Laboratories (Pakistan) Research & Development Related Terms

Abbott Laboratories (Pakistan) Research & Development Historical Data

* Premium members only.

The historical data trend for Abbott Laboratories (Pakistan)'s Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abbott Laboratories (Pakistan) Research & Development Chart

Abbott Laboratories (Pakistan) Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 84.95 62.09 24.94 81.06 136.36

Abbott Laboratories (Pakistan) Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.80 32.83 31.88 43.85 33.24
KAR:ABOT
77GF Score
Abbott Laboratories (Pakistan) Ltd KAR:ABOT
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abbott Laboratories (Pakistan) Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₨142 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₨142 Mil mean?
Abbott Laboratories (Pakistan) (KAR:ABOT) has a Research & Development of ₨142 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Abbott Laboratories (Pakistan) and its competitors.
Is Abbott Laboratories (Pakistan)'s Research & Development too high?
Abbott Laboratories (Pakistan)'s current Research & Development is ₨142 Mil. Overall, Abbott Laboratories (Pakistan) has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories (Pakistan)'s Research & Development compare to ZTS and UTHR?
Abbott Laboratories (Pakistan)'s Research & Development of ₨142 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Abbott Laboratories (Pakistan) and its competitors. Abbott Laboratories (Pakistan)'s current Research & Development is ₨142 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories (Pakistan) stock overvalued right now?
Based on GuruFocus' analysis, Abbott Laboratories (Pakistan) (KAR:ABOT) is currently considered Fairly Valued. The stock's GF Value™ is ₨1,001.38, compared to a current price of ₨966.44 — trading 3.5% below its estimated fair value. The current Research & Development is ₨142 Mil. Abbott Laboratories (Pakistan)'s overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Abbott Laboratories (Pakistan) (KAR:ABOT), the current Research & Development is ₨142 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abbott Laboratories (Pakistan) (KAR:ABOT) Overvalued in 2026?

Based on GuruFocus' analysis, Abbott Laboratories (Pakistan) stock appears to be undervalued. The current stock price of ₨966.44 is trading 3.5% below its estimated GF Value™ of ₨1,001.38. GuruFocus considers Abbott Laboratories (Pakistan) to be Fairly Valued.

Key valuation signals for KAR:ABOT:

  • Research & Development: ₨142 Mil
  • GF Value™: ₨1,001.38 vs. price of ₨966.44 (3.5% below fair value)
  • GF Score™: 77/100 with 2 warning signs

No single metric tells the full story. See the KAR:ABOT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abbott Laboratories (Pakistan) Business Description

Address Hyderabad Road, Landhi, P.O. Box 7229, Plot No. 258 & 324, Opposite Radio Pakistan Transmission Centre, Karachi, PAK, 75120
Abbott Laboratories (Pakistan) Ltd manufactures, imports, and markets research-based pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital, and consumer products. Its operating segments are Pharmaceutical, Nutritional, Diagnostics, and Others. It generates maximum revenue from the Pharmaceutical segment. Geographically, it derives the majority of its revenue from Pakistan and has a presence in Afghanistan, Sri Lanka, Bangladesh, and Switzerland. The company's Brands include Duphaston, Brufen, Surbex Z, Arinac, Glucerna, Pediasure, and Ensure.
77GF Score

Get the complete analysis for KAR:ABOT

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨966.44
Price
₨1,001.38
GF Value